BioCentury | Jan 23, 2021
Emerging Company Profile

Technology showcase: BioCentury’s 2020 class of emerging companies

As emerging therapeutic modalities move toward mainstream, a flood of new companies has arisen to break through the limitations of first-generation technologies and expand the reach of gene and cell therapies,...
BioCentury | Dec 31, 2020
Product Development

Dec. 30 Quick Takes: Approval for Sinopharm vaccine follows report of 79% protection; plus Aprea, Axsome, Serum Institute, Pfizer-BioNTech, Moderna, Inotrem and Actinium

...proposal’s terms, the company would begin distributing the mRNA-based COVID-19 vaccine in May 2021.France designates Inotrem’s TREM-1...
...S.A. a national research priority. The designation facilitates accelerated patient enrollment and regulatory reviews. The TREM-1...
BioCentury | Dec 17, 2020
Emerging Company Profile

Vigil: restoring the vigilance of microglia

Incubated by Atlas Venture and led by former Ipsen CBO Ivana Magovčević-Liebisch, Vigil launched last week with $50 million in series A financing to advance two TREM2 agonists in-licensed from Amgen in rare microgliopathy indications. “We’ve...
BioCentury | Dec 10, 2020
Finance

Dec. 9 Quick Takes: Nuance leads bolus of venture rounds for China’s innovators; plus launches for Hillhouse’s Overland, OSI’s PepGen and Atlas’ Vigil and more

CBC portfolio company Nuance closes $181M series DNuance Biotech raised $181 million in a series D round led by RTW Investments and GT Fund with participation by existing investors CBC Group, Matrix Partners China and...
BioCentury | Jun 24, 2020
Deals

Gilead gains access to tumor myeloid targets via Pionyr partnership

Gilead’s tie-up with Pionyr marks the big biotech’s fifth cancer deal this year and gives it access to mAbs against immunosuppressive tumor myeloid cells. In an agreement announced Tuesday, Gilead Sciences Inc. (NASDAQ:GILD) will pay...
BioCentury | May 30, 2020
Tools & Techniques

Denali offers rare peek into the science behind its CNS delivery platform

Denali is lifting the veil on the delivery technology it’s using to transport large molecules into the CNS, detailing a differentiated strategy for hijacking the transferrin receptor. The company revealed features of its large molecule...
BioCentury | Feb 13, 2020
Finance

Feb. 12 Financial Quick Takes: Trio of follow-ons; plus Teva, PentixaPharm, Inotrem

Theravance, Adverum, Moderna price follow-ons With a $148.5 million offering, Theravance Biopharma Inc. (NASDAQ:TBPH) was among at least three biotechs raising follow-ons after-market Tuesday. The company sold 5.5 million shares at $27, a 12% discount...
BioCentury | Sep 12, 2019
Financial News

Inotrem raises €39M series B for septic shock therapy, diagnostic

A €39 million ($43 million) series B round raised by Inotrem will allow the French biotech to get its lead program for septic shock through Phase IIb testing. Morningside Ventures led the round, with participation...
BioCentury | Aug 29, 2019
Preclinical News

Aug. 29 Preclinical Quick Takes: New targets for leukemia from Calico and stroke from Gero; predictors of checkpoint inhibitor response and more

Calico finds new target for sensitizing leukemia to NK cells Calico Life Sciences LLC (South San Francisco, Calif.) showed in an eLife paper that blocking DCAF15, an adaptor for E3 ubiquitin ligase substrates, could boost...
BioCentury | Aug 15, 2019
Translation in Brief

New target bolsters TREM2's role in Alzheimer's

A new gene linked to TREM2 reinforces the microglial receptor's role in Alzheimer's and could offer a way to treat the disease. As the Alzheimer's field looks beyond β amyloid for new pathways and targets,...
Items per page:
1 - 10 of 51